Staphylococcal scalded skin syndrome: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 2: Line 2:
'''For patient information, click [[Staphylococcal scalded skin syndrome (patient information)|here]]'''
'''For patient information, click [[Staphylococcal scalded skin syndrome (patient information)|here]]'''


{{SI}}
{{SSSS}}
{{CMG}}
{{CMG}}



Revision as of 15:24, 11 December 2012

For patient information, click here

Staphylococcal scalded skin syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Staphylococcal scalded skin syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Staphylococcal scalded skin syndrome On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Staphylococcal scalded skin syndrome

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Staphylococcal scalded skin syndrome

CDC on Staphylococcal scalded skin syndrome

Staphylococcal scalded skin syndrome in the news

Blogs on Staphylococcal scalded skin syndrome

Directions to Hospitals Treating Staphylococcal scalded skin syndrome

Risk calculators and risk factors for Staphylococcal scalded skin syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: Ritter's disease; pemphigus neonatorum; localized bullous impetigo; SSSS.

Overview

Staphylococcal scalded skin syndrome is a dermatological condition caused by Staphylococcus aureus.

Pathophysiology

The syndrome is induced by epidermolytic exotoxins (exfoliatin)[1] A and B, which are released by S. aureus and cause detachment within the epidermal layer; by breaking down tight-junctions. One of the exotoxins is produced by the bacterial chromosome, while the other is produced by a plasmid. (Bacterial plasmids are pieces of self-replicating DNA that often code for secondary characteristics, such as antibiotic resistance, and toxin production.) These exotoxins are proteases that cleave desmoglein-1, which normally holds the granulosum and spinosum layers together.

Signs and Symptoms

The disease presents with the widespread formation of fluid filled blisters that are thin walled and easily ruptured and the patient can be positive for Nikolsky's sign. Ritter's Disease of the Newborn is the most severe form of SSSS with similar signs and symptoms. SSSS often includes a widespread painful erythroderma, often involving the face, diaper, and other intriginous areas. Extensive areas of desquamation might be present. Perioral crusting and fissuring are seen early in the course. Unlike toxic epidermal necrolysis, SSSS spares the mucous membranes. It is most common in children under 6 years, but can be seen in adults who are immunosuppressed or have renal failure.

Diagnosis

The diagnosis of SSSS is made clinically. This is sometimes confirmed by isolation of S. aureus from blood, mucous membranes, or skin biopsy; however, these are often negative. Skin biopsy may show separation of the superficial layer of the epidermis, differentiating SSSS from TEN, wherein the epidermal-dermal layer is separated in the latter. SSSS may be difficult to distinguish from toxic epidermal necrolysis and pustular psoriasis.

Treatment

The mainstay of treatment for SSSS is supportive care along with eradication of the primary infection. Conservative measures include rehydration, antipyretics, management of thermal burns, and stabilization. Parenteral antibiotics to cover S. aureus should be administered. Most strains of S. aureus implicated in SSSS have penicillinases, and are therefore penicillin resistant. Therefore, treatment with Nafcillin, oxacillin, or vancomycin is typically indicated. Clindamycin is sometimes also used because of its inhibition of exotoxins.

Prognosis

The prognosis of SSSS in children is excellent, with complete resolution within 10 days of treatment, and without significant scarring. However, SSSS must be differentiated carefully from toxic epidermal necrolysis, which carries a poor prognosis. The prognosis in adults is generally much worse, and depends upon various factors such as time to treatment, host immunity, and comorbidities.

History

The clinical features were first described in 1878 by Baron Gottfried Ritter von Rittershain, who observed 297 cases among children in a single Czechoslovakian children's home over a 10-year period.[2]

See also

References

  1. Template:DorlandsDict
  2. Mockenhaupt M, Idzko M, Grosber M, Schöpf E, Norgauer J (2005). "Epidemiology of staphylococcal scalded skin syndrome in Germany". J. Invest. Dermatol. 124 (4): 700–3. doi:10.1111/j.0022-202X.2005.23642.x. PMID 15816826. Unknown parameter |month= ignored (help)

Template:Cutaneous infections

Template:Cutaneous-infection-stub

ca:Síndrome de la pell escaldada estafilocòccica de:Staphylococcal scalded skin syndrome nl:Staphylococcal scalded skin syndrome sl:Stafilokokni eksfoliativni dermatitis sv:Staphylococcal scalded skin syndrome